FABP2 and myeloid sarcoma: Butyrate was furthermore inversely correlated with plasma levels of lipopolysaccharide (LPS) and intestinal fatty acid-binding protein (I-FABP), suggesting that the butyrate reduction was responsible for the increased intestinal barrier permeability that has previously been described in MS patients (35, 36).